Tesamorelin
peptideevidence: established · v1.0.0Description
Tesamorelin is a stabilized analog of GHRH studied in lipid-distribution and growth-hormone-axis research. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.
Mechanism summary
GHRH receptor agonist; GH axis modulation.
How it works
Tesamorelin tells your pituitary gland (the small gland in your brain that controls growth hormone) to release more growth hormone (GH) in its natural rhythm. That extra GH then drives the body to break down deep belly fat and liver fat more than other fat stores.
GHRH Receptor Binding Your pituitary has docking points called GHRH receptors. Tesamorelin locks onto these receptors and turns on the same signaling pathways (cAMP and PKA) your body uses naturally. The result is a normal-shaped pulse of GH release, not a constant flood.
IGF-1 Increase Once GH enters the bloodstream, the liver makes more IGF-1 (insulin-like growth factor 1). IGF-1 carries out many of GH's downstream effects on fat and tissue. Trials show IGF-1 rises while other pituitary hormones stay in their normal ranges.
Fat Breakdown The GH and IGF-1 rise drives fat breakdown in visceral fat (the deep fat around your organs) more than in fat under the skin. It also reduces fat buildup in the liver. Phase III trials and NAFLD studies confirmed these effects, which is what earned tesamorelin its FDA approval.
Feedback Stays Intact Unlike injecting growth hormone directly (which can shut off your body's own GH production), tesamorelin keeps your normal feedback loops. Your brain still controls the system. Tesamorelin only amplifies the signal your body already sends. [Source: Peptide Dosing Protocols]
In plain language
Tesamorelin helps your body release more growth hormone, which in turn helps break down belly fat and liver fat while maintaining normal hormone regulation.
Reference details
Route(s)
subcutaneous
Tags
hormone, metabolic
Active
yes
Product details · TSM10
Price
$87.99
Stock
out of stock
Mol. weight
5135.9 g/mol
Formula
C221H366N72O67S
Purity
≥ 99%
CAS #
218949-48-5
COA: View certificate (batch TET-4288-A) →
Teton Labs product catalog · research-use compound data.
💉 Dosing — 3 references (verbatim from source · not a recommendation)
Dose
1-2 mg SC daily at bedtime
Route
subcutaneous
Frequency
once daily at bedtime
Duration
12+ weeks
Cycle
Continuous per provider direction
Reconstitution
Reconstitute with sterile/bacteriostatic water
Vial
Commonly 2 mg vials
Source: Practitioner Peptide Dosing Reference (commonly published ranges) — Compiled practitioner reference (internal_protocol)Source-backedProvider-reviewed
Dose
2 mg
Route
subcutaneous
Frequency
Once daily
Source: Peptide Protocol Wiki (peptideprotocolwiki.com) (publication)Source-backedProvider-reviewed
Dose
Standard: 2 mg once a day
Route
Subcutaneous injection in the abdomen only
Frequency
Once daily
Duration
26 weeks
Cycle
Cycle length Planning note 4 weeks 6 vials (10 mg) 28 daily doses needed.
Reconstitution
Reconstitute with bacteriostatic water
Source: Peptide Dosing Protocols (peptidedosingprotocols.com) (publication)Source-backedProvider-reviewed
Safety, contraindications & monitoring
Contraindications — who should avoid
- Use is contraindicated in patients with a known hypersensitivity to tesamorelin or any of its components.
Safety & side effects
- Side effects may include injection site reactions, headache, and nausea.
Monitoring & bloodwork
- CBC at baseline and week 4
Clinical evidence
- Trials showed effects reverse when stopped.
- Sustained therapy is generally needed to keep results.
Source-backedProvider-reviewedApproved findings drawn from your sources — decision support, not medical advice.
Provider-only reference. This page does not constitute medical advice, a recommendation, or dosing guidance.